(Q28378826)

1

0 references

H Saito

2

0 references

H Tomioka

3

0 references

K Sato

4

0 references

J Jidoi

5

0 references

K Hosoe

6

0 references

T Hidaka

Antimicrobial Agents and Chemotherapy

7

0 references

language of work or name

English

0 references

publication date

October 1995

0 references

published in

0 references

volume

39

0 references

issue

10

0 references

page(s)

2295-303

0 references

cites work

In vitro antimicrobial activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex, determined by the radiometric method

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162932

The emergence of drug-resistant tuberculosis in New York City

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162932

Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162932

Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162932

Therapeutic efficacy of the benzoxazinorifamycin KRM-1648 against experimental Mycobacterium avium infection induced in rabbits

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162932

Mechanism of action of antimycobacterial activity of the new benzoxazinorifamycin KRM-1648

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162932

In vitro activities of new rifamycin derivatives against Mycobacterium tuberculosis and M. avium complex

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162932

In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162932

In vivo activities of new rifamycin derivatives against mycobacteria

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162932

An outbreak of tuberculosis caused by multiple-drug-resistant tubercle bacilli among patients with HIV infection

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162932

An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162932

Multiple-drug-resistant tuberculosis: clinical and laboratory issues

20 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162932

Multidrug-resistant tuberculosis and its control

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162932

Drug-resistant tuberculosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162932

The epidemiology of tuberculosis in the United States

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162932

Synthesis and biological activity of 3'-hydroxy-5'-aminobenzoxazinorifamycin derivatives

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162932

Determination of minimal inhibitory concentrations of antituberculosis drugs by radiometric and conventional methods

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162932

The impact of HIV infection on the global epidemiology of tuberculosis

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162932

Hospital outbreak of multidrug-resistant Mycobacterium tuberculosis infections. Factors in transmission to staff and HIV-infected patients.

2 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=162932

Therapeutic effect of KRM-1648 with various antimicrobials against Mycobacterium avium complex infection in mice

2 June 2018

1 reference

12 December 2020

A rapid [3H]glycerol radioassay for determination of monocyte-mediated growth inhibition of Mycobacterium avium

1 reference

12 December 2020

Tuberculosis in patients with human immunodeficiency virus infection

1 reference

12 December 2020

Multidrug-resistant tuberculosis

1 reference

12 December 2020

In vitro and in vivo activities of KRM-1648, a newly synthesized benzoxazinorifamycin, against Mycobacterium marinum

1 reference

12 December 2020

Treatment and prevention of multidrug-resistant tuberculosis

1 reference

12 December 2020

In vivo antileprosy activity of the newly synthesized benzoxazinorifamycin, KRM-1648

1 reference

12 December 2020